These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32763582)

  • 1. Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia.
    Feld J; Navada SC; Silverman LR
    Leuk Res; 2020 Oct; 97():106430. PubMed ID: 32763582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luspatercept in Myelodysplastic Syndromes: Who and When?
    Komrokji RS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
    Chan O; Komrokji RS
    Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luspatercept: First Approval.
    Markham A
    Drugs; 2020 Jan; 80(1):85-90. PubMed ID: 31939073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
    Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
    N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.
    Mies A; Hermine O; Platzbecker U
    Curr Hematol Malig Rep; 2016 Dec; 11(6):416-424. PubMed ID: 27595736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
    Molica M; Rossi M
    Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
    Kang C; Syed YY
    Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapies in low- and high-risk myelodysplastic syndrome.
    Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
    Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
    [No Abstract]   [Full Text] [Related]  

  • 10. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes.
    Verma A; Suragani RN; Aluri S; Shah N; Bhagat TD; Alexander MJ; Komrokji R; Kumar R
    J Clin Invest; 2020 Feb; 130(2):582-589. PubMed ID: 31961337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
    Garcia-Manero G; Mufti GJ; Fenaux P; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Ilhan O; Sekeres MA; Zeidan AM; Ito R; Zhang J; Rampersad A; Sinsimer D; Backstrom JT; Platzbecker U; Komrokji RS
    Blood; 2022 Jan; 139(4):624-629. PubMed ID: 34758066
    [No Abstract]   [Full Text] [Related]  

  • 12. New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat.
    Tefferi A
    Am J Hematol; 2021 Jul; 96(7):761-763. PubMed ID: 33861878
    [No Abstract]   [Full Text] [Related]  

  • 13. Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS.
    Komrokji RS
    Curr Hematol Malig Rep; 2019 Aug; 14(4):346-351. PubMed ID: 31203517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activin receptor ligand traps in chronic kidney disease.
    Jelkmann W
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):351-357. PubMed ID: 29847322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lowering the boom on lower-risk myelodysplastic syndromes.
    Sekeres MA; Patel BJ
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):367-372. PubMed ID: 31808873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.
    Fenaux P; Kiladjian JJ; Platzbecker U
    Blood; 2019 Feb; 133(8):790-794. PubMed ID: 30602619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Approaches for Anemia in MDS.
    Platzbecker U
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S59-S60. PubMed ID: 32862871
    [No Abstract]   [Full Text] [Related]  

  • 19. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
    Park S; Kelaidi C; Meunier M; Casadevall N; Gerds AT; Platzbecker U
    Ann Hematol; 2020 Jan; 99(1):7-19. PubMed ID: 31650290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells.
    Wobus M; Mies A; Asokan N; Oelschlägel U; Möbus K; Winter S; Cross M; Weidner H; Rauner M; Hofbauer LC; Bornhäuser M; Platzbecker U
    Leukemia; 2021 Oct; 35(10):2936-2947. PubMed ID: 34002031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.